Publication AWA
At the Public Information Bulletin of the Agency for Health Technology Assessment and Tarification (AWA) has published reviews analyses for the evaluation of reimbursement applications:
- Tepkinly (epcoritamab) in the treatment of patients with B-cell lymphomas
- Ozurdex (dexamethasone) in the treatment of patients with retinal diseases
We encourage you to read the full documents and submit comments within the prescribed period of 7 days from the date of publication.
